Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-naïve Patients.

Reichmuth, Martina L.; Hömke, Rico; Zürcher, Kathrin; Sander, Peter; Avihingsanon, Anchalee; Collantes, Jimena; Loiseau, Chloé; Borrell, Sonia; Reinhard, Miriam; Wilkinson, Robert J; Yotebieng, Marcel; Fenner, Lukas; Böttger, Erik C; Gagneux, Sebastien; Egger, Matthias; Keller, Peter Michael (2020). Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-naïve Patients. Antimicrobial agents and chemotherapy, 64(11), e00513-20. American Society for Microbiology 10.1128/AAC.00513-20

Preview

Text Reichmuth_AntimicrobAgentsChemother_2020.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (276kB) | Preview

Mutations in the genes of the F420 signaling pathway, including dnn, fgd1, fbiA, fbiB, fbiC, and fbiD, of Mycobacterium tuberculosis (Mtb) complex can lead to delamanid resistance. We searched for such mutations among 129 Mtb strains from Asia, South-America, and Africa using whole-genome sequencing; 70 (54%) strains had at least one mutation in one of the genes. For ten strains with mutations, we determined the minimum inhibitory concentration (MIC) of delamanid. We found one strain from a delamanid-naïve patient carrying the natural polymorphism Tyr29del (ddn) that was associated with a critical MIC to delamanid.

Interest & Impact

Downloads

91 since deposited on 09 Sep 2020
30 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item